9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma

CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 336

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Overall survival,  modified RECIST or RECIST 1.1 – progression free survival,  modified RECIST or RECIST 1.1 – overall response rate, EQ-5D-5L

Interventions: Nivolumab, Placebo

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Primary Purpose: Treatment

Primary Completion Date: June 2021

Completion Date: July 2021

Last  Posted Date: August 5, 2019

Location: Ulster Hospital, Dundonald, Belfast, United Kingdom

Website Link: https://ClinicalTrials.gov/show/NCT03063450

Was this article helpful?
Dislike 0